Synonym
Trifluperidol; Trifluperidol hydrochloride; R-2498; R 2498; R2498
IUPAC/Chemical Name
1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one hydrochloride
InChi Key
VYGQXRZAHIZHQV-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H23F4NO2.ClH/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26;/h1,3-4,6-9,15,29H,2,5,10-14H2;1H
SMILES Code
O=C(C1=CC=C(F)C=C1)CCCN2CCC(C3=CC=CC(C(F)(F)F)=C3)(O)CC2.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
749-13-3 (Trifluperidol)
2062-77-3 (Trifluperidol Hydrochloride)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
445.88
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Szenohradszky J, Gibiszer PK, Pórszász J Jr, Gács E. Effects of beta adrenergic blocking drugs and trifluperidol on intestinal motility and splanchnic nerve activity in cats. Acta Chir Hung. 1983;24(4):307-21. PubMed PMID: 6670434.
2: Fortes ZB. The effect of trifluperidol on the contractile response of guinea-pig taenia coli to acetylcholine, histamine, potassium and calcium. Gen Pharmacol. 1984;15(5):423-5. PubMed PMID: 6510679.
3: Kowalski J, Labuzek K, Herman ZS. Flupentixol and trifluperidol reduce interleukin-1 beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Pol J Pharmacol. 2004 Sep-Oct;56(5):563-70. PubMed PMID: 15591644.
4: Kowalski J, Labuzek K, Herman ZS. Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-alpha and nitric oxide by rat microglial cells. Neurochem Int. 2003 Jul;43(2):173-8. PubMed PMID: 12620286.
5: Coughenour LL, Cordon JJ. Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes. J Pharmacol Exp Ther. 1997 Feb;280(2):584-92. PubMed PMID: 9023267.
6: Singh SP, Giridhar C, Avasthi A. Neuroleptic malignant syndrome with trifluperidol. Br J Psychiatry. 1989 Oct;155:561-3. PubMed PMID: 2611583.
7: Marcucci F, Airoldi L, Mussini E, Garattini S. Distribution of haloperidol and trifluperidol in brain and blood of rats. Chem Biol Interact. 1972 May;4(6):427-30. PubMed PMID: 5030587.
8: Lewi PJ, Heykants JJ, Janssen PA. On the distribution and metabolism of neuroleptic drugs. 3. Pharmacokinetics of trifluperidol. Arzneimittelforschung. 1970 Nov;20(11):1701-5. PubMed PMID: 5536974.
9: Janssen PA, Allewijn FT. The distribution of the butyrophenones haloperidol, trifluperidol, moperone, and clofluperol in rats, and its relationship with their neuroleptic activity. Arzneimittelforschung. 1969 Feb;19(2):199-208. PubMed PMID: 5818759.
10: BISHOP MP, GALLANT DM. TRIFLUPERIDOL IN "PARANOID" AND "NON-PARANOID" SCHIZOPHRENICS. Curr Ther Res Clin Exp. 1965 Feb;7:96-101. PubMed PMID: 14260091.
